Clinical trials
Metastatic Liver Cancer clinical trials
Below are recruiting metastatic liver cancer clinical trials, each written for real people, not researchers. We’re tracking 817 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06084897RecruitingPhase 2
Radiotherapy for metastatic esophageal cancer responding to immunotherapy
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06946901RecruitingPhase 2
Heated chemo in abdomen plus IV chemo for pancreatic cancer
This trial tests a treatment that combines heating chemotherapy drugs and delivering them directly into the abdomen (HIPEC) with standard chemotherapy through a vein. It is for people whose pancreatic cancer has spread to the lining of the abdomen but not to other organs, and who have not had prior cancer treatment.
Changsha, HunanAges 18–80 - NCT06654037RecruitingPhase 1
Testing abemaciclib plus 5-FU for advanced colorectal cancer
This trial is testing whether adding a targeted drug called abemaciclib to the standard chemotherapy 5-FU can help people with a specific type of advanced colorectal cancer (MSS) that has stopped responding to other treatments. The goal is to see if this combination is safe and effective.
Irvine, CaliforniaAges 18 years+ - NCT07300241RecruitingPhase 1
Study of NEO-811 for advanced kidney cancer
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT06606990RecruitingPhase 1
Testing the drug CX-5461 for advanced solid tumors
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
Bethesda, MarylandAges 18 years+ - NCT07607678RecruitingPhase 1
Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
New Haven, ConnecticutAges 18 years+ - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT07718490RecruitingPhase 2
Immunotherapy with simvastatin and chemo for advanced colorectal cancer
This trial tests a new combination of immunotherapy, simvastatin (a cholesterol drug), and standard chemotherapy for advanced colorectal cancer that has not been treated before. The goal is to see if adding simvastatin can help the immune system fight the cancer better.
Nanjing, JiangsuAges 18–75 - NCT07504523RecruitingPhase 1
Personalized T-cell therapy for advanced colorectal cancer
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
Hangzhou, ZhejiangAges 18–70 - NCT06792695RecruitingPhase 2
Study of new treatments for colorectal cancer
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Scottsdale, ArizonaAges 18–130 - NCT06681818Recruiting
New method to measure liver regrowth after surgery
This study tests a new way to measure how well your liver grows back and heals after part of it is removed. The goal is to predict and prevent complications after surgery.
Englewood, New JerseyAges 18 years+ - NCT06105684RecruitingPhase 2
Low-dose capecitabine for advanced breast cancer
This trial tests a lower dose of the chemotherapy drug capecitabine in people with advanced breast cancer that is HER2 negative. It aims to see if this gentler dose works well, especially for older or frailer patients who may have more difficulty with standard treatment.
Birmingham, AlabamaAges 60 years+ - NCT05927857RecruitingPhase 1/Phase 2
Testing three medicines for advanced stomach cancer after first treatment
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
Taipei, Taiwan/TaipeiAges 20–80 - NCT05011383RecruitingPhase 2
High-dose testosterone for prostate cancer with certain gene changes
This trial tests whether high doses of testosterone, a male hormone, can help slow or shrink prostate cancer that has stopped responding to usual hormone treatments, specifically in people whose tumors have changes in the ATM, CDK12, or CHEK2 genes.
Aurora, ColoradoAges 18 years+ - NCT01954992RecruitingPhase 3
Glufosfamide vs 5-FU for metastatic pancreatic cancer after gemcitabine
This study compares two chemotherapy drugs—glufosfamide and 5-FU—in people with pancreatic cancer that has spread and got worse after gemcitabine. It aims to see which option works better as a “second-line” treatment.
Whittier, CaliforniaAges 18 years+ - NCT05004116RecruitingPhase 1/Phase 2
Repotrectinib plus chemotherapy for relapsed solid tumors in youth
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
New York, New YorkAges 1–25 - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT06589440RecruitingPhase 2
Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Morristown, New JerseyAges 18 years+ - NCT06998108RecruitingPhase 3
A new drug with fulvestrant for HR+/HER2- advanced breast cancer
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06630416RecruitingPhase 2
Pemetrexed for advanced bladder and other cancers with certain gene changes
This trial tests if a chemotherapy drug called pemetrexed works better in advanced bladder cancer or other solid tumors that have specific genetic changes (MLL4, UTX, or MTAP). It is for people who have already tried at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT06820255RecruitingPhase 4
DNA repair and platinum chemo for advanced bladder cancer
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
RomeAges 18 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT07543744RecruitingPhase 1
Comparing RPH-030 to Vectibix for metastatic colorectal cancer
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
ArkhangelskAges 18 years+
Hear when a new Metastatic Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic liver cancer?
- Yes. Clin2 currently lists 817 recruiting metastatic liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.